Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

Sandborn, William J.; Hanauer, S. B.; Rutgeerts, P.; Fedorak, Richard N.; Lukas, M; MacIntosh, Donald; Panaccione, Remo; Wolf, Douglas C.; Kent, Jeffrey D.; Bittle, Barry; Ju, Li; Pollack, P

doi:10.1136/gut.2006.106781

articleGutFeb 13, 2007BRONZE OA

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

WJWilliam J. Sandborn SBS. B. Hanauer PRP. Rutgeerts RNRichard N. FedorakMLM Lukas

Mayo Clinic · University of Illinois Chicago · +12 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial.

Objective

To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II).

Citation impact

1,033

total citations

FWCI: 41.64
Percentile: 100%
References: 34

Citations per year

Authors

12

Topics & keywords

Topics

Keywords

Adalimumab
Medicine
Crohn's disease
Placebo
Internal medicine
Maintenance therapy
Surgery
Gastroenterology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.